— IND filing for ADU-1805 expected in Q1 2023, delivering Exelixis with the opportunity to expand its clinical pipeline —
— ADU-1805 may have broad applicability in multiple tumor types, including solid tumors —
Exelixis, Inc. EXEL and Sairopa BV (Sairopa) announced today that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially first-in-class monoclonal antibody targeting SIRPα. SIRPα, expressed on myeloid cells, interacts with CD47 present on the surface of cancer cells and blocks the ability of macrophages to clear tumor cells by phagocytosis and inhibits the presentation of tumor antigens to T cells. Blocking SIRPα has the potential to enhance the immune system’s ability to attack tumors by targeting a significant immunosuppressive component of the tumor microenvironment. ADU-1805 is active against all human alleles of SIRPα, which may allow it to target a broader patient population than other SIRPα-targeted therapies. ADU-1805 has also been optimized to preferentially bind to SIRPα over other members of the SIRP family, which could enhance its ability to stimulate immune cells.
This press release is multimedia. Check out the full release here: https://www.businesswire.com/news/home/20221101005989/en/
“ADU-1805 is a promising antibody that has been carefully optimized to maximize the potential benefit of blocking the SIRPα-CD47 checkpoint while minimizing potential toxicities and…
